Eczema
Recent clinical, regulatory, research and industry developments relating to this disease.
Marketing authorisation: Anzupgo (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q3 2027.
- 12 industry developments reported.
- Q3 2027A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
- Q3 2027A Phase IV, Non-randomized, Open-label Multinational Trial to Assess the Mechanism of Action for Lebrikizumab in Moderate-to-severe Atopic Dermatitis
- Q4 2027A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
- Q2 2028A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Q1 2032A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis
Clinical MilestonesView all 14Hide
- 2026-08-05A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic DermatitisResults posted
- 2025-12-23A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic DermatitisResults posted
- 2026-09-25A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic DermatitisResults expected Q1 2032
- 2026-09-15A Phase IV, Non-randomized, Open-label Multinational Trial to Assess the Mechanism of Action for Lebrikizumab in Moderate-to-severe Atopic DermatitisResults expected Q3 2027
- 2026-09-14A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisResults expected Q2 2028
- 2026-09-08A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic DermatitisResults expected Q4 2027
- 2026-07-27A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic DermatitisResults expected Q3 2027
- 2026-08-26A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Moderate to Severe Atopic DermatitisCompleted
- 2026-08-19A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) When Used In Combination With Topical Corticosteroid Treatment (TCS) in Participants With Moderate to Severe Atopic Dermatitis.Completed
- 2026-04-23A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic DermatitisCompleted
- 2026-01-12A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate LNK01001 in Adults Subjects With Moderate to Severe Atopic Dermatitis.Completed
- 2026-07-08A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Upadacitinib on Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis (SLEEP UP)Withdrawn
- 2026-07-01A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)Terminated
- 2026-01-13A Single-Center, Open-Label Study to Evaluate Tralokinumab in Atopic Dermatitis Subjects Who Experienced Inadequate Response on DupilumabTerminated
Industry & MarketView all 12Hide
- 2026-09-30Apogee buy delivers eczema trial win for AbbVieAcquisition · pharmaphorum
- 2026-09-17North Immunology goes public via reverse merger as eczema drug heads toward clinicAcquisition · Fierce Biotech
- 2026-11-02STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival DupixentTrial news · STAT News
- 2026-10-01Pfizer’s eczema drug clears skin in mid-stage trialTrial news · BioPharma Dive
- 2026-09-30AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117Trial news · Endpoints News
- 2026-11-02IndustrySTAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival DupixentTrial news · STAT News
- 2026-10-14IndustryEczema Proteomics Differ by Drug Class, Analysis FindsIndustry · Medscape Medical News
- 2026-10-13IndustryTriple-Targeting Tilrekimig Eases Established EczemaIndustry · Medscape Medical News
- 2026-10-01IndustryPfizer’s eczema drug clears skin in mid-stage trialTrial news · BioPharma Dive
- 2026-09-30IndustryAbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117Trial news · Endpoints News
- 2026-09-30IndustryApogee buy delivers eczema trial win for AbbVieAcquisition · pharmaphorum
- 2026-09-25ClinicalA Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic DermatitisResults expected Q1 2032
- 2026-09-17IndustryNorth Immunology goes public via reverse merger as eczema drug heads toward clinicAcquisition · Fierce Biotech
- 2026-09-15IndustryAAD Issues Guidelines on Treatment-Refractory Adult EczemaIndustry · Medscape Medical News
- 2026-09-15ClinicalA Phase IV, Non-randomized, Open-label Multinational Trial to Assess the Mechanism of Action for Lebrikizumab in Moderate-to-severe Atopic DermatitisResults expected Q3 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Original application approval — Anzupgo is indicated for the treatment of moderate to severe chronic hand eczema (CHE) (2024)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes6
- Dermatitis, Atopic2
- Eczema2
- Cytokines1
- Health Care Costs1
- Immune Checkpoint Inhibitors1
- Quality of Life1
Leading journals5
- Clinical cancer research : an official journal of the American Association for Cancer Research1
- Journal of the European Academy of Dermatology and Venereology : JEADV1
- Lancet (London, England)1
- The British journal of dermatology1
- The Journal of investigative dermatology1
Leading researchers8
- Wollenberg A3
- Cork MJ2
- Simpson EL2
- Thyssen JP2
- Aschoff R1
- Bang A1
- Bang B1
- Barbarot S1
Affiliations (unnormalised)6
- Herlev-Gentofte Hospital2
- Ludwig Maximilian University of Munich2
- Oregon Health & Science University2
- University of Sheffield2
- Aarhus University Hospital1
- Alpert Medical School of Brown University1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Eczema is a dermatitis marked by a spongiotic tissue reaction pattern. It occurs as a reaction to many endogenous and exogenous agents. The supplied grounding does not further distinguish subtypes beyond atopic dermatitis in the review abstract.
It is described as a reaction to many endogenous and exogenous agents. The grounding does not specify particular causes or aetiologies beyond this broad reactive framework.
The defining biological pattern is spongiotic dermatitis, indicating a spongiotic tissue reaction pattern. No additional mechanistic details are provided in the grounding.
The grounding does not identify specific risk factors for eczema. The review abstract only notes that atopic dermatitis can affect quality of life, family life, occupation, and economic burden, which are impacts rather than risk factors.
The supplied grounding does not describe standard treatment or drug classes for eczema. It only addresses the burden of atopic dermatitis and does not provide therapeutic guidance.
AI-generated summary grounded in MeSH and 1 peer-reviewed source. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A dermatitis characterized by a spongiotic tissue reaction pattern occurring as a reaction to many endogenous and exogenous agents.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.